Published August 26, 2026 Updated August 27, 2026 7 min read

# Intensive blood pressure control and dementia risk in APOE4 carriers

## The short version

Intensive blood-pressure lowering is still one of the few dementia levers with a real trial behind it. The 2026 split suggests carriers may prevent more dementia in absolute terms. It does not prove Alzheimer prevention or a special APOE4 blood-pressure target.

By the OutliveAPOE4 editorial team. [How we research & source](/methodology).

Among APOE4 carriers in SPRINT, aiming for systolic blood pressure under 120 instead of under 140 went with a 1.7 percentage-point lower dementia risk over four years. That is about one fewer case for every 59 people treated. In people without ε4, the same comparison was essentially a wash. [\[1\]](/topics/sprint-apoe4-intensive-blood-pressure#ref-xu-2026-sprint-apoe)

SPRINT is a large randomized blood-pressure trial. This genotype split is a July 2026 secondary analysis, posted as a preprint, not a finished journal paper. The relative drop in dementia looked larger in carriers, but that difference was not statistically clear. The absolute gap was. Both facts belong next to the headline, not in a footnote.

## What this page answers

-   Did intensive blood-pressure lowering prevent more dementia in APOE4 carriers?
-   Why the absolute number is the useful one
-   What this does not change about your target

## What the 2026 SPRINT split measured

SPRINT randomized 9,361 adults aged 50 and older with high blood pressure and extra heart risk, but without diabetes, prior stroke, or dementia. One group aimed for systolic pressure under 120 mm Hg. The other aimed for under 140. [\[3\]](/topics/sprint-apoe4-intensive-blood-pressure#ref-sprint-nct)

The original thinking results, SPRINT MIND, found about a 19% lower risk of mild cognitive impairment with the intensive target. That is a hazard ratio of 0.81, meaning a lower instantaneous risk in the intensive arm, not a 19% cut in each person’s lifetime odds. Probable dementia was 17% lower (hazard ratio 0.83), with a confidence interval that crossed no effect. [\[2\]](/topics/sprint-apoe4-intensive-blood-pressure#ref-sprint-mind-2019)

Yizhe Xu, Adam Bress, and colleagues then genotyped stored DNA. Of 7,733 people with both genotype and outcome data, 29% carried at least one ε4 allele: 2,049 with one copy and 192 with two. Over a median 5.1 years, dementia rates under intensive versus standard treatment were 9.7 versus 13.2 cases per 1,000 people per year in carriers (hazard ratio 0.73). In non-carriers they were 6.1 versus 6.7 (hazard ratio 0.91). A test of whether those two relative effects differed came back not significant. [\[1\]](/topics/sprint-apoe4-intensive-blood-pressure#ref-xu-2026-sprint-apoe)

The absolute scale is where the carrier story lives. After accounting for people who died without dementia, the 4-year dementia risk difference was −1.7% in carriers versus +0.2% in non-carriers. That absolute-scale difference *was* statistically significant. [\[1\]](/topics/sprint-apoe4-intensive-blood-pressure#ref-xu-2026-sprint-apoe)

That pattern is what you expect when baseline risk is higher. Independently of treatment, ε4 carriage itself tracked with an 82% higher dementia hazard in this cohort (hazard ratio 1.82). Give two groups a similar relative trim, and the group that started higher loses more cases in absolute terms. Carriers had more dementia to prevent, so the same blood-pressure program bought more.

## Why blood pressure is a carrier-specific lever

APOE4 is not only an amyloid gene. The ε4 protein is worse at moving lipids, and it is tied to earlier breakdown of the blood-brain barrier, the tight seal that keeps the wrong things out of brain tissue. Chronically high pressure then damages the small vessels that feed and drain that tissue. The two insults sit on the same plumbing. For the mechanism tour, see [how APOE4 affects the brain](/topics/how-apoe4-affects-the-brain) and the [brain–heart axis](/topics/brain-heart-axis-vascular-cognitive-decline).

A separate 2025 randomized trial in rural China asked a related question without genotype. In the China Rural Hypertension Control Project, 33,995 adults with untreated high blood pressure joined a community program that cut systolic pressure by about 22 mm Hg. All-cause dementia fell 15% over 48 months (risk ratio 0.85). [\[4\]](/topics/sprint-apoe4-intensive-blood-pressure#ref-he-2025-crhcp) It is not an APOE4 paper. It is independent randomized evidence that treating high pressure lowers dementia, not only mild cognitive impairment.

## Dementia rates under intensive versus standard control

| What | Figure | Context |
| --- | --- | --- |
| SPRINT MIND, mild cognitive impairment | HR 0.81 (~19% lower) | published 2019; not split by genotype |
| SPRINT MIND, probable dementia | HR 0.83 (CI 0.67–1.04) | not statistically significant |
| 2026 analysis, dementia in ε4 carriers | 9.7 vs 13.2 per 1,000 people-years; HR 0.73 (CI 0.51–1.04) | intensive vs standard |
| 2026 analysis, dementia in non-carriers | 6.1 vs 6.7 per 1,000 people-years; HR 0.91 (CI 0.67–1.23) | intensive vs standard |
| Did the relative effects differ? | P = 0.35 | not statistically clear |
| 4-year absolute risk difference, carriers | −1.7% (~59 people treated to prevent one case) | accounts for death without dementia |
| 4-year absolute risk difference, non-carriers | +0.2% | accounts for death without dementia |
| Did the absolute effects differ? | P = 0.045 | the carrier-specific finding |
| ε4 vs non-carrier dementia hazard, any treatment | HR 1.82 (CI 1.44–2.29) | genotype as a risk factor inside SPRINT |
| China rural trial 2025, all-cause dementia | RR 0.85 (CI 0.76–0.95) | 33,995 people; not APOE-stratified |

## What this preprint cannot tell you

Treat this as a secondary analysis posted as a preprint in July 2026. It has not gone through journal peer review, and the authors did not adjust for running several comparisons. The study was too small to be sure the treatment effect truly differs by genotype. SPRINT also stopped the blood-pressure intervention early after the heart result came in, which shrinks the pressure gap and the number of dementia cases. Extended telephone follow-up through 2023 still pointed the same way in carriers (6-year risk difference −1.0%), but the confidence interval crossed zero. [\[1\]](/topics/sprint-apoe4-intensive-blood-pressure#ref-xu-2026-sprint-apoe)

SPRINT also enrolled a specific group: high heart risk, no diabetes, no prior stroke. About 36% were women. Intensive targets can cause lightheadedness, falls, and kidney-function dips in some older adults, which is why the number you aim for is a conversation, not a universal 120. For how to measure and talk about the target, stay with [blood pressure and brain health](/topics/blood-pressure-and-brain-health). For how to read a secondary analysis without over-weighting it, see [reading a study like a skeptic](/topics/reading-a-study-like-a-skeptic).

## How to use this with a clinician

Nothing here says “get to 119 because you carry ε4.” It says the randomized evidence that intensive control helps thinking is at least as relevant to you as to anyone else. The new analysis argues the *absolute* payoff may be larger because your baseline dementia risk is higher.

-   **Know the number.** Home readings, seated, arm at heart height, after five minutes of rest. One high reading at the clinic is a poor guide.
-   **Bring genotype in as context, not as a prescription.** If you have high pressure, the case for treating it is already strong. Carrying ε4 is a reason not to shrug it off.
-   **Ask about a target.** Guidelines have been moving toward under 130/80 mm Hg for many adults at elevated risk, with some encouragement toward 120 when it is tolerated. Your age, kidneys, fall risk, and other medicines decide the rest.
-   **Keep the other vascular levers.** The trial did not replace [exercise](/topics/exercise-and-apoe4), sleep, or lipid control. It added a pressure target on top of them.

## Common questions

**Does this mean APOE4 carriers should aim for under 120?** Not as a blanket rule. It is a reason to take intensive control seriously with a clinician who can weigh the brain benefit against dizziness, falls, and kidney effects.

**Is a preprint good enough to act on?** The parent trial is published. The genotype split is new and not yet journal-reviewed. Use it as supportive context for a lever you already had reason to pull, not as a new drug-like claim.

**What if my pressure is already treated?** Stay treated. The signal is about *how low*, in a high-risk trial population, not about abandoning therapy that is already working.

> High blood pressure is still one of the few dementia levers backed by large trials. The 2026 SPRINT split says carriers may have more absolute dementia to prevent with the same target. Set the number with a clinician.

## References

1.  \[1\] [Xu et al. 2026, medRxiv: Effect of intensive vs standard blood pressure control according to APOE ε4 genotype, a secondary analysis of SPRINT](https://www.medrxiv.org/content/10.64898/2026.07.02.26357167) [↩](/topics/sprint-apoe4-intensive-blood-pressure#cite-xu-2026-sprint-apoe)
2.  \[2\] [SPRINT MIND Investigators, 2019, JAMA: Intensive vs standard blood pressure control and probable dementia](https://pubmed.ncbi.nlm.nih.gov/30688979/) [↩](/topics/sprint-apoe4-intensive-blood-pressure#cite-sprint-mind-2019)
3.  \[3\] [ClinicalTrials.gov NCT01206062: Systolic Blood Pressure Intervention Trial (SPRINT)](https://clinicaltrials.gov/study/NCT01206062) [↩](/topics/sprint-apoe4-intensive-blood-pressure#cite-sprint-nct)
4.  \[4\] [He et al. 2025, Nature Medicine: Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension (CRHCP)](https://www.nature.com/articles/s41591-025-03616-8) [↩](/topics/sprint-apoe4-intensive-blood-pressure#cite-he-2025-crhcp)

## Related deep dives

-   [Blood pressure and brain health High blood pressure is one of the best-established modifiable risk factors for dementia. Why it matters so much for APOE4 carriers, the numbers, and how to keep it in range.](/topics/blood-pressure-and-brain-health)
-   [The brain-heart axis: how blood vessels shape cognitive decline Much of what we call "Alzheimer’s" is tangled up with vascular damage. Why protecting your blood vessels is also protecting your memory, and what that means for carriers.](/topics/brain-heart-axis-vascular-cognitive-decline)
-   [Reading a study like a skeptic: a carrier’s media-literacy guide APOE4 headlines swing from "cure" to "doom" weekly. A practical toolkit for reading health studies and news so you can tell real signal from hype, and act on the right things.](/topics/reading-a-study-like-a-skeptic)
-   [How APOE4 affects the brain APOE4 influences how the brain clears amyloid, handles tau, manages inflammation, regulates neural activity, and maintains its blood vessels. A plain-language tour of the leading mechanisms.](/topics/how-apoe4-affects-the-brain)